Trial Profile
A trial to study the effectiveness and survival-on-drug of certolizumab pegol in a real-life setting, both in TNFi-naive patients and in patients who had previously failed TNFis, and in relation to disease activity at baseline.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 20 May 2016 New trial record